Treating Periodontal Diseases by Blocking Tissue-destructive Enzymes
Overview
Affiliations
A new therapeutic approach involves the discovery by the "Stony Brook group," that tetracyclines, but not other antibiotics, can inhibit host-derived collagen-destructive enzymes. This newly discovered property of tetracyclines is unrelated to the antimicrobial activity of these drugs. Examples support the hypothesis that this unexpected property of tetracyclines provides a new approach to treating periodontal diseases as well as a variety of medical disorders.
Pavanelli A, de Menezes B, Pereira E, de Souza Morais F, Cirelli J, de Molon R Biomed Res Int. 2022; 2022:5832009.
PMID: 35547360 PMC: 9085331. DOI: 10.1155/2022/5832009.
Katsiki P, Nazmi K, Loos B, Laine M, Schaap K, Hepdenizli E J Clin Periodontol. 2021; 48(9):1250-1259.
PMID: 33998029 PMC: 8453974. DOI: 10.1111/jcpe.13479.
Dalhoff A Infection. 2020; 49(1):29-56.
PMID: 33367978 PMC: 7851017. DOI: 10.1007/s15010-020-01536-y.
Dehdashtizadeh A, Esnaashari N, Farhad S, Ejeian F, Amini S Dent Res J (Isfahan). 2020; 17(3):213-218.
PMID: 32774799 PMC: 7386378.
Chemically-Modified Curcumin 2.24: A Novel Systemic Therapy for Natural Periodontitis in Dogs.
Deng J, Golub L, Lee H, Lin M, Bhatt H, Hong H J Exp Pharmacol. 2020; 12:47-60.
PMID: 32104105 PMC: 7020920. DOI: 10.2147/JEP.S236792.